{"product_id":"ifrx-marketing-mix","title":"(IFRX) InflaRx N.V. Marketing Mix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis InflaRx N.V. 4P's Marketing Mix Analysis explains the company’s product offerings, pricing approach, distribution channels, and promotional tactics in a concise, actionable format; the page includes a real preview\/sample so you can evaluate style and content before buying. Purchase the full version to receive the complete, ready-to-use analysis for strategy, benchmarking, or presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVilobelimab, first-in-class anti-C5a mAb\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVilobelimab is InflaRx N.V.’s lead asset and the core of its pipeline. This first-in-class anti-C5a monoclonal antibody is designed to block C5a, a key driver of inflammation, and is given intravenously. In 2025, InflaRx reported R\u0026amp;D spending of €22.5 million, underscoring how central Vilobelimab remains to product investment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHidradenitis suppurativa, Phase III completed\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVilobelimab has completed Phase III in hidradenitis suppurativa, a rare, chronic, painful inflammatory skin disease, making it InflaRx N.V.'s most advanced pipeline asset. In HS, published estimates put prevalence around 0.1% to 1%, and a successful launch could target a small but high-need specialty market with limited approved options.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAAV, Phase II ongoing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInflaRx N.V.'s AAV candidate is in Phase II testing in anti-neutrophil cytoplasm antibody-associated vasculitis, a rare autoimmune disease that affects about 30 to 40 people per million in Europe each year and can cause organ failure. That focus fits the company’s push into severe inflammatory disorders with high unmet need. In a small patient pool, clinical proof of benefit matters more than broad volume.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCSCC, Phase II ongoing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVilobelimab is in Phase II for PD-1 and PD-L1 inhibitor resistant or refractory locally advanced or metastatic cutaneous squamous cell carcinoma, keeping InflaRx N.V. in a narrow, high-need oncology-inflammation niche. Phase II means the product is still proving signal, dose, and safety before any larger readout.\u003c\/p\u003e\n\u003cp\u003eThis is a specialty indication, not a broad-market one, so the value case depends on strong response data in a small, hard-to-treat patient pool. In 2025, the main commercial lever is clinical differentiation, not volume.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePhase II, ongoing\u003c\/li\u003e\n\u003cli\u003ePD-1 and PD-L1 resistant cSCC\u003c\/li\u003e\n\u003cli\u003eSpecialized oncology-inflammation use\u003c\/li\u003e\n\u003cli\u003eClinical proof drives value\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eINF904 oral; IFX002 preclinical\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInflaRx N.V. broadens its pipeline with INF904, a second drug candidate given as an oral small molecule, and IFX002, a preclinical program for chronic inflammation and autoimmune disease. These two assets reduce reliance on vilobelimab and give the Company Name more shots at value creation across different stages of development. One is clinical-stage oral convenience; the other is an early-stage inflammation bet.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eINF904: oral small molecule\u003c\/li\u003e\n\u003cli\u003eIFX002: preclinical program\u003c\/li\u003e\n\u003cli\u003eFocus: chronic inflammation and autoimmunity\u003c\/li\u003e\n\u003cli\u003eMix: beyond vilobelimab\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflaRx’s Pipeline Stays Focused on Vilobelimab and Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInflaRx N.V.’s Product mix is still centered on vilobelimab, a Phase III anti-C5a antibody for hidradenitis suppurativa and Phase II cSCC. The pipeline also includes INF904, an oral small molecule, and IFX002, a preclinical asset. In 2025, R\u0026amp;D spending was €22.5 million, showing continued product focus.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStatus\u003c\/th\u003e\n\u003cth\u003eUse\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVilobelimab\u003c\/td\u003e\n\u003ctd\u003ePhase III \/ II\u003c\/td\u003e\n\u003ctd\u003eHS, cSCC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eINF904\u003c\/td\u003e\n\u003ctd\u003eClinical\u003c\/td\u003e\n\u003ctd\u003eOral inflammation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIFX002\u003c\/td\u003e\n\u003ctd\u003ePreclinical\u003c\/td\u003e\n\u003ctd\u003eAutoimmune\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eDelivers a concise, company-specific 4P's analysis of InflaRx N.V.’s marketing strategy, covering product, price, place, and promotion with real-world context.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eCondenses InflaRx N.V.’s 4Ps into a quick, clear snapshot, easing fast review and strategic alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, traceable bibliography of primary industry reports, regulatory filings, and peer-reviewed data to speed due diligence and validate InflaRx assumptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePlace\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJena, Germany headquarters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInflaRx N.V. is headquartered in Jena, Germany, its main corporate base. The site anchors administration, research oversight, and strategic coordination for a company that reported cash and cash equivalents of $54.7 million at year-end 2025. That base supports day-to-day control of its clinical and operating work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOperations in the United States\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInflaRx N.V. also operates in the United States, extending its footprint beyond Germany and supporting clinical, regulatory, and business development work. That U.S. base matters because U.S. FDA engagement is critical for drug development, and the company’s lead asset, vilobelimab, has been advanced through U.S.-linked clinical work. In 2025, InflaRx N.V. reported no product revenue and continued to rely on cash resources to fund operations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial site distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFor InflaRx N.V., clinical trial site distribution is the core access point, not retail channels, because vilobelimab, INF904, and IFX002 move through hospital and investigator sites under protocol control. Trial materials are shipped directly to study centers, which keeps dosing, safety checks, and data capture tightly managed across clinical-stage programs. This model fits a biotech with no commercial launch yet, so site coverage drives patient reach and enrollment speed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCo-development with Beijing Defengrei\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInflaRx N.V.'s co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. gives it a partner-led route into broader regional development. It also signals planned China-linked development activity, which can lower local execution risk versus a solo push.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartner-based regional expansion\u003c\/li\u003e\n\u003cli\u003eChina-linked development presence\u003c\/li\u003e\n\u003cli\u003eShared local execution capacity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSupply collaboration with Merck\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInflaRx N.V. has a clinical trial collaboration and supply agreement with Merck \u0026amp; Co., Inc., which gives it access to study supply and helps run trials on time. This is a development channel, not a commercial sales route. It matters most for clinical execution because it reduces supply and logistics risk in late-stage studies.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMerck supports study supply access.\u003c\/li\u003e\n\u003cli\u003eUsed for clinical development, not sales.\u003c\/li\u003e\n\u003cli\u003eHelps trial execution and continuity.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflaRx’s Market Access Is Trial-Driven, Not Sales-Led\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInflaRx N.V. uses Jena, Germany, as its main operating base, with U.S. presence for clinical and regulatory work. In 2025, it held $54.7 million in cash and cash equivalents, so its place strategy stays centered on funded trial execution, not sales coverage. Its real market access points are hospital and investigator sites for vilobelimab, INF904, and IFX002, plus partner-led routes in China and trial support through Merck.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eInflaRx N.V. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual InflaRx N.V. 4P's Marketing Mix Analysis you’ll receive instantly after purchase—no surprises.\u003c\/p\u003e\n\u003cp\u003eThis is the same ready-made, editable document you'll download immediately after checkout, fully complete and ready to use.\u003c\/p\u003e\n\u003cp\u003eYou’re viewing the exact version of the analysis included in your order; buy with full confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePromotion\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial milestones\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInflaRx N.V. uses clinical trial milestones as a core promotion tool, highlighting phase progress to signal pipeline strength. Its phase III hidradenitis suppurativa program and ongoing phase II and phase IIa studies show active clinical depth, which supports scientific credibility and investor interest. Clear readouts and updates help turn trial progress into measurable pipeline value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific and medical communications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInflaRx N.V.’s promotion is aimed mainly at physicians, researchers, and investors, with conference posters and medical data disclosures doing the heavy lifting. In biotech, these channels explain mechanism, safety, and efficacy fast, which matters when one clinical readout can re-rate a stock; InflaRx’s vilobelimab program has been reported across major immunology and dermatology meetings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInvestor relations disclosure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInflaRx N.V. leans on investor relations disclosure as a core promotion tool, using earnings releases, annual reports, and corporate presentations to keep investors updated on trial progress and funding needs. For a clinical-stage company with no product revenue, these updates are one of the main ways to build credibility and support the share price.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartnership announcements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMerck and Beijing Defengrei partnerships do more than support InflaRx N.V.'s pipeline; they act as promotional proof points. Two external alliances signal shared development skill and raise trust with partners, investors, and clinicians. In biotech, that kind of validation can matter as much as cash.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2 named collaborations boost credibility\u003c\/li\u003e\n\u003cli\u003eSignal external validation\u003c\/li\u003e\n\u003cli\u003eSupport market awareness and trust\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRegulatory and trial registry visibility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClinical trial registrations and regulatory filings make InflaRx N.V.'s pipeline public. ClinicalTrials.gov holds 500,000+ studies, and many U.S. interventional trials must be posted within 21 days of first enrollment, so rare-disease and oncology work stays visible to clinicians, investors, and partners.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow-cost public promotion\u003c\/li\u003e\n\u003cli\u003eSignals pipeline progress\u003c\/li\u003e\n\u003cli\u003eSupports partner outreach\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflaRx’s 2025–2026 Growth Signal: Trials, Partnerships, and Data\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInflaRx N.V. promotes itself mainly through clinical data, conference updates, and investor disclosures, since it has no product sales. Its 2025–2026 value signal comes from vilobelimab’s phase III hidradenitis suppurativa work and phase II\/IIa studies, plus named alliances with Merck and Beijing Defengrei. Trial registrations also keep the pipeline visible to clinicians and investors.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePromotion lever\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003cth\u003e2025–2026 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical milestones\u003c\/td\u003e\n\u003ctd\u003ePipeline strength\u003c\/td\u003e\n\u003ctd\u003ePhase III, II, IIa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartnerships\u003c\/td\u003e\n\u003ctd\u003eExternal validation\u003c\/td\u003e\n\u003ctd\u003e2 named collaborations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic filings\u003c\/td\u003e\n\u003ctd\u003eLow-cost visibility\u003c\/td\u003e\n\u003ctd\u003eClinicalTrials.gov 500,000+ studies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePrice\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo marketed product price disclosed\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInflaRx N.V. has no marketed product price disclosed because it remains a clinical-stage company. As of the latest public filings, pricing is not publicly set for vilobelimab, INF904, or IFX002, and there are no commercial sales to anchor list pricing. That means any future price will depend on trial results, regulatory approval, and payer talks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrecommercial pricing stage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInflaRx N.V.'s lead asset is still in development, so price is not yet a customer-facing lever; there are 0 commercial sales today. Any future price will hinge on FDA\/EMA approval, label breadth, and payer reimbursement, which is standard for biotech before launch. In this stage, value is built on clinical data, not list price.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRare disease premium potential\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInflaRx N.V.'s lead targets are rare, severe diseases: hidradenitis suppurativa affects about 1% to 4% of people, and AAV incidence is roughly 10 to 20 cases per million each year. That kind of niche often supports premium biologic pricing if clinical benefit is clear, but payers will still push back hard on total value and durability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHospital-administered biologic economics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVilobelimab is an IV monoclonal antibody, so pricing would be tied to hospital and infusion-center economics, not retail shelf price. In 2025, InflaRx reported vilobelimab was still a hospital-administered asset, so site-of-care fees, chair time, and nursing use matter. This usually lifts total treatment cost well above drug-only price.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eHospital billing will include administration costs.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eInfusion-center site-of-care drives economics.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eNot an OTC or pharmacy-retail model.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartner-funded development economics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInflaRx N.V.'s partner-funded development model can blunt cash outlay: the Merck and Beijing Defengrei deals may share R\u0026amp;D costs before launch, which can ease pressure on the company’s own balance sheet and support more flexible pricing later. In 2025, this matters because lower net spend can help preserve cash for C5a pipeline work.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCost sharing lowers InflaRx N.V.'s upfront burden.\u003c\/li\u003e\n\u003cli\u003ePartner payments can offset development risk.\u003c\/li\u003e\n\u003cli\u003ePricing power may rise after shared pre-launch costs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflaRx Pricing Hinges on Approval, Coverage, and Rare-Disease Demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrice is not set yet because InflaRx N.V. has no marketed product and no commercial sales in 2025. Future pricing for vilobelimab will depend on FDA\/EMA approval, payer coverage, and site-of-care costs for IV dosing. For rare diseases like hidradenitis suppurativa and AAV, premium pricing is possible if clinical benefit is clear.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial sales\u003c\/td\u003e\n\u003ctd\u003e0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVilobelimab price\u003c\/td\u003e\n\u003ctd\u003eNot disclosed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHS prevalence\u003c\/td\u003e\n\u003ctd\u003e1% to 4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAAV incidence\u003c\/td\u003e\n\u003ctd\u003e10 to 20 per million\/year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234528502025,"sku":"ifrx-marketing-mix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/ifrx-marketing-mix.webp?v=1785721678","url":"https:\/\/dcfanalyst.com\/products\/ifrx-marketing-mix","provider":"DCF Analyst","version":"1.0","type":"link"}